nsg mouse model Search Results


ll/2 metastasis in nsg mouse model  (Johns Hopkins HealthCare)
90
Johns Hopkins HealthCare ll/2 metastasis in nsg mouse model
(A) In vitro transfection efficiencies of nanoparticles (W1–W8, see Table 1) in PC3 cancer cell line (dose = 0.6 μg gWiz-Luc plasmid/104 cells); (B) In vivo transfection efficiency in the lung in <t>healthy</t> <t>BALB/c</t> mice at 12 h post i.v. injection of nanoparticles (W1–W8, see Table 1) containing 40 μg gWiz-Luc plasmid per mouse (left) and representative IVIS images of groups with significant differences in transgene expression (right); (C) In vivo transfection efficiency in the lung of an LL/2 metastasis model in the <t>NSG</t> mice at 48 h post injection of nanoparticles (P1-P8, see Table 1) containing 40 μg PEG-Luc plasmid per mouse (left) and representative IVIS images of groups with significant differences in transgene expression (right); (D) Whole-body biodistributions in BALB/c mice at 1 h post injection of nanoparticles (W1, W2, W6, W8) containing 40 μg 3H-labeled gWiz-Luc plasmid per mouse. Labels: H: heart, K: kidneys, S: stomach, SI: small intestine; (E) Biodistributions to the lung of mice shown in (D); For statistical analysis, n.s. denotes no statistical significance with p > 0.05, *p < 0.05, **p < 0.01, and ***p < 0.001 from one-way or two-way ANOVA and multiple comparisons.
Ll/2 Metastasis In Nsg Mouse Model, supplied by Johns Hopkins HealthCare, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nsg+mouse+model/ll+2+metastasis+in+nsg+mouse+model/pmc07293580-653-41-44
Average 90 stars, based on 1 article reviews
ll/2 metastasis in nsg mouse model - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
nsg-15 humanized mouse model  (Brehm GmbH)
90
Brehm GmbH nsg-15 humanized mouse model
(A) In vitro transfection efficiencies of nanoparticles (W1–W8, see Table 1) in PC3 cancer cell line (dose = 0.6 μg gWiz-Luc plasmid/104 cells); (B) In vivo transfection efficiency in the lung in <t>healthy</t> <t>BALB/c</t> mice at 12 h post i.v. injection of nanoparticles (W1–W8, see Table 1) containing 40 μg gWiz-Luc plasmid per mouse (left) and representative IVIS images of groups with significant differences in transgene expression (right); (C) In vivo transfection efficiency in the lung of an LL/2 metastasis model in the <t>NSG</t> mice at 48 h post injection of nanoparticles (P1-P8, see Table 1) containing 40 μg PEG-Luc plasmid per mouse (left) and representative IVIS images of groups with significant differences in transgene expression (right); (D) Whole-body biodistributions in BALB/c mice at 1 h post injection of nanoparticles (W1, W2, W6, W8) containing 40 μg 3H-labeled gWiz-Luc plasmid per mouse. Labels: H: heart, K: kidneys, S: stomach, SI: small intestine; (E) Biodistributions to the lung of mice shown in (D); For statistical analysis, n.s. denotes no statistical significance with p > 0.05, *p < 0.05, **p < 0.01, and ***p < 0.001 from one-way or two-way ANOVA and multiple comparisons.
Nsg 15 Humanized Mouse Model, supplied by Brehm GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nsg+mouse+model/nsg+15+humanized+mouse+model/pm36351384-176-8-38
Average 90 stars, based on 1 article reviews
nsg-15 humanized mouse model - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
nsg mouse model of cd5+ t-cell leukemia  (CEM Corporation)
90
CEM Corporation nsg mouse model of cd5+ t-cell leukemia
(A) In vitro transfection efficiencies of nanoparticles (W1–W8, see Table 1) in PC3 cancer cell line (dose = 0.6 μg gWiz-Luc plasmid/104 cells); (B) In vivo transfection efficiency in the lung in <t>healthy</t> <t>BALB/c</t> mice at 12 h post i.v. injection of nanoparticles (W1–W8, see Table 1) containing 40 μg gWiz-Luc plasmid per mouse (left) and representative IVIS images of groups with significant differences in transgene expression (right); (C) In vivo transfection efficiency in the lung of an LL/2 metastasis model in the <t>NSG</t> mice at 48 h post injection of nanoparticles (P1-P8, see Table 1) containing 40 μg PEG-Luc plasmid per mouse (left) and representative IVIS images of groups with significant differences in transgene expression (right); (D) Whole-body biodistributions in BALB/c mice at 1 h post injection of nanoparticles (W1, W2, W6, W8) containing 40 μg 3H-labeled gWiz-Luc plasmid per mouse. Labels: H: heart, K: kidneys, S: stomach, SI: small intestine; (E) Biodistributions to the lung of mice shown in (D); For statistical analysis, n.s. denotes no statistical significance with p > 0.05, *p < 0.05, **p < 0.01, and ***p < 0.001 from one-way or two-way ANOVA and multiple comparisons.
Nsg Mouse Model Of Cd5+ T Cell Leukemia, supplied by CEM Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nsg+mouse+model/nsg+mouse+model+of+cd5++t+cell+leukemia/10__1182_slash_blood___2023___187665-15-28-31
Average 90 stars, based on 1 article reviews
nsg mouse model of cd5+ t-cell leukemia - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
mouse nv nsg hil15  (Shanghai Model Organisms Center)
86
Shanghai Model Organisms Center mouse nv nsg hil15
(A) In vitro transfection efficiencies of nanoparticles (W1–W8, see Table 1) in PC3 cancer cell line (dose = 0.6 μg gWiz-Luc plasmid/104 cells); (B) In vivo transfection efficiency in the lung in <t>healthy</t> <t>BALB/c</t> mice at 12 h post i.v. injection of nanoparticles (W1–W8, see Table 1) containing 40 μg gWiz-Luc plasmid per mouse (left) and representative IVIS images of groups with significant differences in transgene expression (right); (C) In vivo transfection efficiency in the lung of an LL/2 metastasis model in the <t>NSG</t> mice at 48 h post injection of nanoparticles (P1-P8, see Table 1) containing 40 μg PEG-Luc plasmid per mouse (left) and representative IVIS images of groups with significant differences in transgene expression (right); (D) Whole-body biodistributions in BALB/c mice at 1 h post injection of nanoparticles (W1, W2, W6, W8) containing 40 μg 3H-labeled gWiz-Luc plasmid per mouse. Labels: H: heart, K: kidneys, S: stomach, SI: small intestine; (E) Biodistributions to the lung of mice shown in (D); For statistical analysis, n.s. denotes no statistical significance with p > 0.05, *p < 0.05, **p < 0.01, and ***p < 0.001 from one-way or two-way ANOVA and multiple comparisons.
Mouse Nv Nsg Hil15, supplied by Shanghai Model Organisms Center, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nsg+mouse+model/hil15+mouse+nsg+nv/pmc12490235-86-0-3
Average 86 stars, based on 1 article reviews
mouse nv nsg hil15 - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier

Image Search Results


(A) In vitro transfection efficiencies of nanoparticles (W1–W8, see Table 1) in PC3 cancer cell line (dose = 0.6 μg gWiz-Luc plasmid/104 cells); (B) In vivo transfection efficiency in the lung in healthy BALB/c mice at 12 h post i.v. injection of nanoparticles (W1–W8, see Table 1) containing 40 μg gWiz-Luc plasmid per mouse (left) and representative IVIS images of groups with significant differences in transgene expression (right); (C) In vivo transfection efficiency in the lung of an LL/2 metastasis model in the NSG mice at 48 h post injection of nanoparticles (P1-P8, see Table 1) containing 40 μg PEG-Luc plasmid per mouse (left) and representative IVIS images of groups with significant differences in transgene expression (right); (D) Whole-body biodistributions in BALB/c mice at 1 h post injection of nanoparticles (W1, W2, W6, W8) containing 40 μg 3H-labeled gWiz-Luc plasmid per mouse. Labels: H: heart, K: kidneys, S: stomach, SI: small intestine; (E) Biodistributions to the lung of mice shown in (D); For statistical analysis, n.s. denotes no statistical significance with p > 0.05, *p < 0.05, **p < 0.01, and ***p < 0.001 from one-way or two-way ANOVA and multiple comparisons.

Journal: ACS nano

Article Title: Kinetic Control in Assembly of Plasmid DNA/Polycation Complex Nanoparticles

doi: 10.1021/acsnano.9b03334

Figure Lengend Snippet: (A) In vitro transfection efficiencies of nanoparticles (W1–W8, see Table 1) in PC3 cancer cell line (dose = 0.6 μg gWiz-Luc plasmid/104 cells); (B) In vivo transfection efficiency in the lung in healthy BALB/c mice at 12 h post i.v. injection of nanoparticles (W1–W8, see Table 1) containing 40 μg gWiz-Luc plasmid per mouse (left) and representative IVIS images of groups with significant differences in transgene expression (right); (C) In vivo transfection efficiency in the lung of an LL/2 metastasis model in the NSG mice at 48 h post injection of nanoparticles (P1-P8, see Table 1) containing 40 μg PEG-Luc plasmid per mouse (left) and representative IVIS images of groups with significant differences in transgene expression (right); (D) Whole-body biodistributions in BALB/c mice at 1 h post injection of nanoparticles (W1, W2, W6, W8) containing 40 μg 3H-labeled gWiz-Luc plasmid per mouse. Labels: H: heart, K: kidneys, S: stomach, SI: small intestine; (E) Biodistributions to the lung of mice shown in (D); For statistical analysis, n.s. denotes no statistical significance with p > 0.05, *p < 0.05, **p < 0.01, and ***p < 0.001 from one-way or two-way ANOVA and multiple comparisons.

Article Snippet: Preliminary tests revealed that the transgene expression level (luciferase concentration in healthy lung tissues or tumor cells in the lung) peaks at around 12 and 48–72 h post injection for healthy BALB/c mouse model (Jackson Laboratory, US) and LL/2 metastasis in NSG mouse model (Johns Hopkins University Animal Core), respectively.

Techniques: In Vitro, Transfection, Plasmid Preparation, In Vivo, Injection, Expressing, Labeling